Q-omics provides the consensus-scored POLR3A profile across patient tissues and cancer cell-line models. POLR3A expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POLR3A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, POLR3A protein abundance shows 23,810 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where POLR3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3A survival associations across molecular data types. POLR3A RNA expression shows survival associations in the most cancer types (30), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3A RNA expression–survival associations across cancer types. High POLR3A expression shows unfavorable associations in ACC, LIHC, BLCA and MESO, but favorable associations in SCLC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for POLR3A RNA expression.
This table summarizes POLR3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for POLR3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3A shows higher tumor expression in HNSC, COAD, LIHC, STAD, LUAD and LUSC. The HNSC box plot shows higher POLR3A RNA expression in tumor versus normal tissue (log2 FC = +0.658, t-test p < 0.001).
This table shows molecular features associated with POLR3A in patient tissues and cancer cell lines. In patient samples, POLR3A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
